77范文网 - 专业文章范例文档资料分享平台

Cell-free DNA Screening for Fetal Aneuploidy-full

来源:网络收集 时间:2021-09-24 下载这篇文档 手机版
说明:文章内容仅供预览,部分内容可能不全,需要完整文档或者需要复制内容,请下载word后使用。下载word有问题请添加微信号:或QQ: 处理(尽可能给您提供完整文档),感谢您的支持与谅解。点击这里给我发消息

国际母胎医学会遗传学专业委员会(Committee on Genetics, Society for Maternal–Fetal Medicine)针对利用游离胎儿DNA筛查非整倍体(cell-free DNA screening for fetal aneuploidy)的建议。

The American College of

Obstetricians and Gynecologists

WOMEN’S HEALTH CARE PHYSICIANS

COMMITTEE OPINION

Number 640 September 2015 Committee on Genetics

Society for Maternal–Fetal Medicine

This document reflects emerging clinical and scientific advances as of the date issued and is subject to change. The information should

not be construed as dictating an exclusive course of treatment or procedure to be followed.

(This Committee Opinion Replaces Committee Opinion Number 545)

Cell-free DNA Screening for Fetal Aneuploidy

ABSTRACT: Noninvasive prenatal screening that uses cell-free DNA from the plasma of pregnant women offers tremendous potential as a screening method for fetal aneuploidy. A number of laboratories have validated different techniques for the use of cell-free DNA as a screening test for fetal aneuploidy. All tests have a high sensitivity and specificity for trisomy 18 and trisomy 21, regardless of which molecular technique is used. Women whose results are not reported, indeterminate, or uninterpretable (a “no call” test result) from cell-free DNA screening should receive further genetic counseling and be offered comprehensive ultrasound evaluation and diagnostic testing because of an increased risk of aneuploidy. Patients should be counseled that cell-free DNA screening does not replace the precision obtained with diagnostic tests, such as chorionic villus sampling or amnio-centesis and, therefore, is limited in its ability to identify all chromosome abnormalities. Cell-free DNA screening does not assess risk of fetal anomalies such as neural tube defects or ventral wall defects. Patients who are undergoing cell-free DNA screening should be offered maternal serum alpha-fetoprotein screening or ultrasound evaluation for risk assessment. The cell-free DNA screening test should not be considered in isolation from other clinical findings and test results. Management decisions, including termination of the pregnancy, should not be based on the results of the cell-free DNA screening alone. Patients should be counseled that a negative cell-free DNA test result does not ensure an unaffected pregnancy. Given the performance of conventional screening methods, the limitations of cell-free DNA screening performance, and the limited data on cost-effectiveness in the low-risk obstetric population, conventional screening methods remain the most appropriate choice for first-line screening for most women in the general obstetric population.

Recommendations

A discussion of the risks, benefits, and alternatives of

various methods of prenatal screening and diagnostic testing, including the option of no testing, should occur with all patients.

Given the performance of conventional screening

methods, the limitations of cell-free DNA screen-ing performance, and the limited data on cost-effectiveness in the low-risk obstetric population, conventional screening methods remain the most appropriate choice for first-line screening for most women in the general obstetric population.

Although any patient may choose cell-free DNA anal-ysis as a screening strategy for common aneuploidies regardless of her risk status, the patient choosing this testing should understand the limitations and benefits

of this screening paradigm in the context of alterna-tive screening and diagnostic options.

The cell-free DNA test will screen for only the com-mon trisomies and, if requested, sex chromosome composition.

Given the potential for inaccurate results and to

understand the type of trisomy for recurrence-risk counseling, a diagnostic test should be recommended for a patient who has a positive cell-free DNA test result.

Parallel or simultaneous testing with multiple

screening methodologies for aneuploidy is not cost- effective and should not be performed.

Management decisions, including termination of the

pregnancy, should not be based on the results of the cell-free DNA screening alone.

VOL. 126, NO. 3, SEPTEMBER 2015 OBSTETRICS & GYNECOLOGY e31

国际母胎医学会遗传学专业委员会(Committee on Genetics, Society for Maternal–Fetal Medicine)针对利用游离胎儿DNA筛查非整倍体(cell-free DNA screening for fetal aneuploidy)的建议。

Women whose results are not reported, indeter-minate, or uninterpretable (a “no call” test result)

from cell-free DNA screening should receive further genetic counseling and be offered comprehensive ultrasound evaluation and diagnostic testing because of an increased risk of aneuploidy.

Routine cell-free DNA screening for microdeletion

syndromes should not be performed.

Cell-free DNA screening is not recommended for

women with multiple gestations.

If a fetal structural anomaly is identified on ultra-

sound examination, diagnostic testing should be offered rather than cell-free DNA screening. Patients should be counseled that a negative cell-free DNA test result does not ensure an unaffected

百度搜索“77cn”或“免费范文网”即可找到本站免费阅读全部范文。收藏本站方便下次阅读,免费范文网,提供经典小说医药卫生Cell-free DNA Screening for Fetal Aneuploidy-full在线全文阅读。

Cell-free DNA Screening for Fetal Aneuploidy-full.doc 将本文的Word文档下载到电脑,方便复制、编辑、收藏和打印 下载失败或者文档不完整,请联系客服人员解决!
本文链接:https://www.77cn.com.cn/wenku/yiyao/1255778.html(转载请注明文章来源)
Copyright © 2008-2022 免费范文网 版权所有
声明 :本网站尊重并保护知识产权,根据《信息网络传播权保护条例》,如果我们转载的作品侵犯了您的权利,请在一个月内通知我们,我们会及时删除。
客服QQ: 邮箱:tiandhx2@hotmail.com
苏ICP备16052595号-18
× 注册会员免费下载(下载后可以自由复制和排版)
注册会员下载
全站内容免费自由复制
注册会员下载
全站内容免费自由复制
注:下载文档有可能“只有目录或者内容不全”等情况,请下载之前注意辨别,如果您已付费且无法下载或内容有问题,请联系我们协助你处理。
微信: QQ: